Stop Guessing Which Drugs Will Hurt Your Patients
A patient on seven medications comes in with fatigue, confusion, and a racing heart. Labs are unremarkable. You adjust a dose, swap a drug, and wait. Three visits later, nothing has changed — because the problem was never the prescription. It was the patient's genome.
Pharmacogenomic (PGx) testing identifies how a patient's genetic variants affect drug metabolism, efficacy, and toxicity — giving prescribers actionable data before an adverse event occurs, not after.
The scale of the underlying problem is hard to overstate. According to a 20-year trend analysis published in BMC Public Health, polypharmacy prevalence among U.S. elderly adults rose from 23.5% to 44.1% between 1999 and 2018 — with rates climbing to 61.7% in adults with heart disease. These are not rare edge cases. They are the majority of a typical primary care panel.
The evidence for acting on this is now landmark-level. The PREPARE trial, published in The Lancet in 2023, showed that genotype-guided prescribing using a 12-gene panel reduced clinically relevant adverse drug reactions by 30% across seven countries — and found that over 93% of enrolled patients had at least one actionable genetic variant.
This guide is for the providers and administrators ready to move from reaction to prevention.
Why Polypharmacy Patients Are at Disproportionate Risk — And Where PGx Testing Fits
Polypharmacy patients are not just managing more medications — they are accumulating more genetic risk with every prescription added. Each drug your patient takes runs through the same metabolic machinery: the CYP450 enzyme system. When a patient's genetic variants make them a poor or ultra-rapid metabolizer of a key enzyme like CYP2D6 or CYP2C19, one prescription becomes a clinical liability. Five prescriptions become a cascade.
The numbers are not subtle. According to PLOS ONE (Young et al., 2021), 65.1% of U.S. adults over 65 seen in physician offices had some form of polypharmacy — with 36.8% on more than five concurrent medications. That is not a niche population. That is the majority of a typical primary care panel.
The harm profile is equally direct. According to StatPearls (citing FDA FAERS data), adverse drug reactions are the fourth leading cause of death in the United States, with nearly 175,000 deaths recorded in 2022 alone.
PGx testing cuts through that risk by answering a question your prescription pad cannot: how does this specific patient process this drug? A one-time genetic panel identifies metabolizer status across the highest-yield pharmacogenes — data that follows the patient into every future prescribing encounter.
CYP2D6, CYP2C19, and SLCO1B1 account for 75% of PGx-preventable ADRs, per PLOS Medicine (Magavern et al., 2025)
A targeted panel covering these genes addresses the vast majority of clinical risk without whole-genome sequencing
Results integrate into EHR workflows, generating automatic alerts at the moment of prescribing — no manual lookup required
This is not a specialty tool. It is a primary care risk management instrument with a measurable evidence base and a clear operational home.
Identifying the Right Patients: Who in Your Panel Should Be Prioritized for PGx Testing
Not every patient needs PGx testing — but the ones who do are probably easier to spot than you think. Start with a simple filter.
Prioritize any patient who meets one or more of these criteria:
On five or more concurrent medications (polypharmacy by clinical definition)
History of unexplained therapeutic failure — a medication that "should have worked" but didn't
Prior adverse drug event, especially one without a clear non-genetic explanation
Currently prescribed from high-risk drug classes: anticoagulants, antidepressants, antiepileptics, opioids, or PPIs
Adults 65+, particularly those managing heart disease or diabetes
That last group is nearly your entire older panel. According to BMC Public Health (2023), polypharmacy affects 61.7% of older adults with heart disease and 57.7% with diabetes.
The upside of acting on these flags is measurable. A clinical decision support pilot in polypharmacy home health patients, cited by Thermo Fisher Scientific referencing the Elliott et al. RCT, reported a 52% reduction in rehospitalization and a 42% reduction in ED visits post-PGx testing.
Run this triage during your existing medication reconciliation workflow. No new infrastructure required — just a sharper lens on patients already flagged for polypharmacy review.
From Results to Action: Integrating PGx Data Into Your Clinical Workflow
A PGx report lands on your desk. Now what? Most providers stall here — not because the data is wrong, but because no one built a clear handoff into the clinical workflow.
Results are typically reported as metabolizer phenotypes: poor, intermediate, normal (extensive), rapid, or ultrarapid. Each category carries a direct prescribing implication:
Poor metabolizers — drug accumulates; standard doses may cause toxicity
Intermediate metabolizers — reduced clearance; consider dose reduction or alternative
Normal/extensive metabolizers — standard dosing applies
Rapid/ultrarapid metabolizers — drug clears too fast; standard doses may be subtherapeutic
The real workflow bottleneck is not interpreting the result — it's making sure it fires automatically the next time that patient is prescribed a relevant drug. According to a systematic review published in JMIR (2024), only 9 of 32 PGx implementation studies mentioned interoperability standards, and only 4 offered actual solutions.
That gap is where clinical value gets lost. Document phenotype results in a discrete EHR field — not a PDF attachment — so clinical decision support alerts can fire at the prescribing moment, regardless of which provider is writing the order.
Brief the full care team: pharmacist, MA, and any co-managing specialists. One-time testing generates lifetime-use data — only if the workflow is built to surface it.
The Practice-Level Case for Offering PGx Testing: Outcomes, Risk, and Patient Trust
Non-optimized medications cost the U.S. healthcare system $528 billion in 2016 — more than what was spent on the drugs themselves, according to the Office of Congressman Dan Crenshaw. Proponents of the Right Drug Dose Now Act estimate PGx-guided prescribing could cut that waste by 30% or more. That is not a research aspiration — that is a direct line to your practice's cost burden and liability exposure.
The downstream numbers for practices are equally hard to ignore:
Hospitalizations and ED visits dropped significantly in MDD patients after PGx testing, per a 2025 real-world dataset study published in PMC
More than 60% of primary care patients in the U.S. and UK are already on medications with PGx recommendations, per the IMPT Study (medRxiv, 2024) — meaning your panel is already affected
CMS Local Coverage Determinations now define clear medical necessity criteria, giving payer reimbursement a documented pathway
When evaluating a PGx vendor, prioritize EHR integration with active CDS alerts — results sitting in a PDF do nothing at the prescribing moment. Also confirm the panel covers CPIC guideline-level A and B genes to meet CMS LCD standards.
Pharmacogenomic testing does not add complexity to prescribing — it removes it. For the polypharmacy patient on six medications who has cycled through three antidepressants without response, or the 70-year-old whose warfarin levels will not stabilize, a one-time test replaces months of trial-and-error with a defensible, data-backed starting point.
The policy environment is moving fast. The bipartisan Right Drug Dose Now Act (H.R. 2471) is pushing federal infrastructure toward genetically informed prescribing. The VA has expanded its PHASER program nationally. CMS Local Coverage Determinations are sharpening the reimbursement criteria. Practices that build PGx workflows now will not be scrambling to catch up when this becomes a standard-of-care expectation for high-risk patients.
As Edward Abrahams, President of the Personalized Medicine Coalition, stated in response to the legislation: "By streamlining activities across multiple federal agencies and health care delivery, this bill would spark more widespread utilization of genetically informed prescribing practices that keep American patients out of the hospital."
That outcome — patients staying out of the hospital — is the clearest ROI a practice can point to.
Schedule a consultation with Perfect Rhythm to explore how pharmacogenomic testing solutions can integrate into your practice workflow.
Download our provider checklist for identifying high-priority PGx testing candidates in your patient panel.
Contact Perfect Rhythm to learn which pharmacogenomic testing platforms are compatible with your current EHR and care protocols.
Frequently Asked Questions
What is pharmacogenomic testing for polypharmacy patients?
Pharmacogenomic (PGx) testing analyzes a patient's genetic variants to predict how they metabolize specific medications. For polypharmacy patients — those on five or more concurrent drugs — it identifies gene-drug interactions that increase the risk of adverse drug reactions or therapeutic failure before those events occur.
Which patients in a primary care panel should be prioritized for PGx testing?
High-priority candidates include adults on five or more concurrent medications, patients with a history of adverse drug events or unexplained therapeutic non-response, and older adults on high-risk drug classes such as anticoagulants, antidepressants, antiepileptics, opioids, or PPIs. According to a recent analysis of the ASPREE trial cohort published on PubMed, 98.8% of older adults carry at least one actionable PGx genotype, making nearly every polypharmacy patient in a senior panel a viable candidate.
How do PGx test results integrate into a primary care workflow?
Results are typically reported as metabolizer status — poor, intermediate, normal, rapid, or ultra-rapid — for specific drug-metabolizing enzymes such as CYP2D6 and CYP2C19. The most operationally effective approach is integrating results directly into the EHR so clinical decision support alerts fire automatically at the point of prescribing, without requiring the clinician to recall genetic data manually.
Does Medicare cover pharmacogenomic testing?
Coverage depends on whether the test meets CMS medical necessity standards under applicable Local Coverage Determinations. According to CMS Medicare Coverage Database LCD L39995, tests must demonstrate actionability through CPIC guideline level A or B, or be listed in the FDA table of known gene-drug interactions. Practices should verify coverage eligibility per patient before ordering.
What is the evidence that PGx testing reduces adverse drug reactions?
The landmark PREPARE trial, published in The Lancet in February 2023 by Swen et al., demonstrated a 30% reduction in clinically relevant adverse drug reactions using a 12-gene pharmacogenomic panel across seven countries. A separate pilot study in polypharmacy home health patients reported a 52% reduction in rehospitalization and a 42% reduction in emergency department visits following PGx-guided prescribing, according to data cited by Thermo Fisher Scientific's Clinical Conversations platform.
